1
MUDr. Radko Komers, CSc.
Publikační činnost k 15.4.2006
Kapitoly v monografiích a učebnicích.
a) zahraniční
Anderson S and Komers R: Renal hemodynamics in experimental diabetes mellitus. In: The Kidney and Hypertension in Diabetes Mellitus, 5th ed.; Mogensen CE ed; Kluwer Academic Publishers, Norwell, Massachusetts, USA, p.281-294, s. 281-294, 2000
Komers R, Anderson S , and Meyer T: Pathophysiology and Nephron Adaptation in Chronic Renal Failure. In: Diseases of the Kidney and Urinary Tract, 7th Edition, Schrier RW ed.,Lippincott Williams & Wilkins, Philadelphia, PA, USA, s. 2689-2117, 2001
Anderson S, Komers R, Brenner BM: Renal and systemic manifestations of glomerular disease. In: The Kidney, 7th Edition, Brenner BM ed., Elsevier Science – Saunders, Oxford, UK, 1927-1955, 2004
Anderson S and Komers R: Renal hemodynamics in experimental diabetes mellitus. In: The Kidney and Hypertension in Diabetes Mellitus, 6th ed.; Mogensen CE ed; Kluwer Academic Publishers, Norwell, Massachusetts, USA, 363-382, 2004
b) tuzemské
Komersová K, Komers R and Sechser T: Hypertension in diabetes mellitus. In: Practical Diabetology; Bartos V and Pelikanova T eds; Maxdorf, 1. vydání, Prague, Czech Republic; 1996
KomersR. , KomersováK. Pelikánová T: Farmakologická léčba hypertenze u pacientů s diabetickou nefropatií. Analýza výsledků studií z posledních let. In: Diabetická nefropatie. Rychlík I, Tesař V. eds. Tigis 2005, 349-374
KomersR: Patofyziologie diabetické nefropatie. In: Onemocnění ledvin a diabetes mellitus. Rychlík I, Tesař V. eds. Tigis 2005, 31-69.
Komers R: Diabetická nefropatie. In: Praktická nefrologie. Teplan V. ed. Grada 2006 str. 269-286.
Články v mezinárodních recenzovaných časopisech.
1.Cooper ME, Vranes D, Vranes DA, Allen TJ, Panagiotopoulos S, Komers R and Jerums G: The effects of dietary cholesterol on experimental diabetic nephropathy. Diabetes Research 22: 159-169, 1993 IF již není k disposci
2. Komers R, Allen TJ and Cooper ME: Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43: 1190-1197, 1994 IF 7.7
3.Cooper ME, Rumble J, Komers R, Du H-C, Jandeleit K, Chou S-T: Diabetes associated mesenteric vascular hypertrophy is attenuated by angiotensin converting enzyme inhibition. Diabetes 43: 1221-1228, 1994 IF 7.7
4.Komers R and Cooper ME: Acute renal hemodynamic effects of angiotensin converting enzyme inhibition in diabetic hyperfiltration: The role of kinins. Am J Physiol 268: F588-F594, 1995 IF 4.13
5.Rumble JR; Komers R; Cooper ME: Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 14: 601-7, 1996
IF 3.64
6.Komers R and CooperME: Renal sodium handling in experimental diabetes: Role of NO. Nephrol Dial Transplant 11: 2170-2177, 1996 IF 2.06
7.Wookey PJ, Cao Z, van Geenen RCI, Voskuil M, Darby IA, Komers R, Cooper ME: Increased density of renal amylin binding sites in experimental of hypertension. Hypertension 30 [part 1]: 455-460; 1997 IF 5.31
8.Komers R and Vrana A: Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 47:215-225, 1998 IF 1.3
9.Komers R, Pelikanová T, and Kazdová L: Effect of hyperinsulinemia on renal function and nitrate/nitrite excretion in the healthy subjects. Clin Exp Pharmacol Physiol 26:336-341, 1999 IF 1.52
10.Komers R, Komersova K, Kazdova L, Ruzickova J, Pelikanova T: Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertension 18:51-9, 2000 IF 3.64
11.Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S: Effects of systemic inhibition of neuronal nitric oxide synthase (NOS1) in diabetic rats. Hypertension 35:655-61, 2000 IF 5.31
12.Komers R and Anderson S: Are ACE inhibitors the best treatment of hypertension in Type 2 diabetes? Current Opinion in Nephrology and Hypertension 9: 173-179, 2000 IF 2.5
13.Komers R, Lindsley JN, Oyama T T, Anderson S: Renal effects of inhibition of neuronal NOS (NOS1) in control and diabetic rats. Am J Physiol 2000, 279:F573-583.
IF 4.13
14.Komers R and Anderson S: Optimal strategies for preventing progression of renal disease: Should ACE inhibitors and angiotensin receptor blockers be used together? Curr Hypertens Rep 2000, 2:465-72. IF 2.3
15.Komers R and Komersova K: Therapeutic potential of ACE inhibitors for the treatment of hypertension in type 2 diabetes. Expert Opin Investig Drugs 2000, 9:2601-2608. IF 3.0
16.Komers R and Anderson S: A review of the treatment of hypertension
diabetic nephropathy. Curr Diabetes Rep 2001, 1:251-260.zatím bez IF
17.Komers R, Jessie N. Lindsley JN, Oyama TT, Schutzer WE, ReedJF, Mader S, and Anderson S:Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001, 107 :889-898.
IF 14.12
18.Komers R, Anderson S, and Epstein M: Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis, 38:1145-1157.
IF 3.69
- Komers R and Epstein M: Cyclooxygenase-2 (COX-2) expression and function in renal pathophysiology. J Hypertension 2002, 20 [Suppl 6]: S11-S15.
IF 3.53
20.Komers R, Tian W, Lindsley JN, Oyama TT, Cohen DM, Anderson S: Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes. J Lab Clin Med 2002, 140:351-357. IF 1.89
21. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S. Endothelial-derived vasoactive mediators in polycystic kidney disease.
Kidney Int. 2003, 63:1776-84. IF 4.93
22.Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney.
Am J Physiol Renal Physiol. 2003, 284:F1121-1137. IF 4.34
23.Komers R, Simkova R, Kazdova L, Ruzickova J, Pelikanova T. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes. J Renin Angiotensin Aldosterone Syst. 2004, 5:33-38.
IF 1.13
24. Vaneckova I, Cahova M, Kramer HJ, Huskova Z, Skaroupkova P, Komers R, Bader M, Ganten D, Cervenka L. Acute effects of cyclooxygenase-2 inhibition on renal function in heterozygous ren-2-transgenic rats on normal or low sodium intake. Kidney Blood Press Res. 2004, 27:203-210. IF 2.4
25. Komers R, Lindsley JN, Oyama TT, Anderson S. Effects of long-term inhibition of neuronal nitric oxide synthase (NOS1) in uninephrectomized diabetic rats. Nitric Oxide. 2004, 11:147-155. IF 2.545
26. Zdychova J, Komers R.Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res. 2005;54(1):1-16.
IF 1.8
27. KomersR, ŽdychováJ,Cahová M, Kazdová L,Lindsley JN, and AndersonS. Renal Cyclooxygenase-2 in Obese Zucker (Fatty) Rats. Kidney Int. 2005, 67: 2151-2158. IF 4.93
28. Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S. Gender Hormones and the Progression of Experimental Polycystic Kidney Disease. Kidney Int. 2005; 68:1729-1739. IF 4.93
29. Horackova M, Schuck O, Komers R, Charvat J, Teplan V, Kvapil M. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2005; 43:413-419. IF 1.755
30.Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, Mader SL,and Anderson S. Altered Endothelial Nitric Oxide Synthase Targeting and Conformation, and Caveolin-1 Expression, in the Diabetic Kidney. Diabetes 2006; 55: 1651-1659. IF 8.03
31.LecianD, Demova H, Lodererova A, Zdychova J, Kluckova H, Teplan V, Voska L, and Komers R. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res. 2006; 29:135-143. IF 2.4
32.Komers R, Lindsley JN, Oyama TT and Sharon Anderson S Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007; 34: 36 –41.
IF 1.437
Články v recenzovaných tuzemských časopisech.
1.Saudek F., Komers R., Bartoš V., Malý J.: Progrese renální insuficience u diabetické nefropatie. Prakt Lek 1990; 70:452-456.
2. Komers R, Malý J, Šimková R: Changes of blood pressure, proteinuria and renal haemodynamics in Type 1 diabetics with manifest diabetic nephropathy after two months captopril treatment. Cas Lek Cesk 1993; 132:359-364.
3.Komers R: Pathophysiological mechanisms of early renal haemodynamic changes in diabetes. Cas Lek Cesk 1996; 135:135-140.
4.Horačková M, Schuck O, Komers R, Teplan V, Charvat J, Kvapil M.
Effects of specific cycloxygenase-2 inhibition on the renal functions of elderly patients with renal function impairment. Cas Lek Cesk 2006;145:777-781.
Články v nerecenzovaných tuzemských časopisech.
4.Komers R: Přehled farmakologických přístupů k léčbě NIDDM. Remedia 2-3/1996, 135-140.
5.Komers R. Kombinace inhibitorů ACE a blokátorů AT1 receptoru v léčbě renálních a kardiovaskulárních onemocnění. Hypertenze 2003; 6: 34-38.
Oponentury, peer reviewing
American Journal of Physiology, Renal Physiology
American Journal of Kidney Diseases
Diabetes
Diabetologia
Clinical and Experimental Pharmacology and Physiology
Nitric Oxide
Kidney International
Hypertension
Nephrology Dialysis Transplantation
Journal of Laboratory and Clinical Medicine
Physiological Research
Kidney and Blood Pressure Research
Redakční rady:American Journal of Physiology, Renal Physiology
Abstrakta: (pouze mezinárodní konference)
1.Vanek I., Bartos V., Straka Z., Komers R., Pavel P., Kocandrle V.: Analysis of Cadaveric Pancreas and Kidney Donor Data With a View to Pancreatic Graft Function Development. In: IV. Congress of the Eur. Society for Organ Transplantation, Barcelona, Spain, 1989
2.Allen T., Cooper M., Komers R., Waldron M., Sastra S., Jerums G.: Long-term Effects of Dietary Sodium On Hyperfiltration In Experimental Diabetes. In: Proceedings of the 11th Annual Scientific Meeting of The Australian Diabetes Society; Adelaide, Australia, 1992
3.Cooper M., Vranes D., Vranes D., Komers R., Jerums G.: Effects of Cholesterol Feeding On Experimental Diabetic Nephropathy. In: Proceedings of the 11th Annual Scientific Meeting of The Australian Diabetes Society; Adelaide, Australia, 1992
4.Komers R, Soulis T, Cooper ME: Effect of nitric oxide inhibition on glomerular hemodynamics and natriuresis in diabetic rats. Diabetologia 36, Suppl 1, A220, 1993
5.Cooper ME, Komers R, Allen TJ: Diabetic hyperfiltration: Role of nitric oxide. In: Proceedings of the 26th Annual Meeting of the American Society of Nephrology, Boston 1993, 573. [ J Amer Soc Nephrol 4: 546, 1993]
6.Rumble J, Komers R, Gleeson A and Cooper ME: Attenuation of diabetes associated mesenteric vascular hypertrophy by ACE inhibition is kini/nitric oxide dependent. In: Proceedings of the 12th Annual Scientific Meeting of The Australian Diabetes Society; Dunedin, New Zealand, 1993.
7.Komers R and Cooper ME: Haemodynamic factors in diabetic hyperfiltration. In: Proceedings the International Satellite Meeting "Hypertension and Diabetes" In Association With the 15th Scientific Meeting of the International Society of Hypertension, Sydney, Australia, 1994
8.Komers R and Cooper ME: Kinins play an important role in the effects of acute angiotensin converting enzyme inhibition in experimental diabetes. European Diabetic Nephropathy Study Group , 7th meeting, Zwolle, The Netherlands, 1994. [Diabetologia 37 (Suppl 1): 719, 1994]
9.Rumble J, Komers R, Cooper ME: Bradykinin / nitric oxide is involved in the antihypertrophic effects of ACE inhibitors (ACEI) on the mesenteric microvessels of the diabetic rat. Diabetologia 37 (Suppl 1): 275, 1994
10.Cooper ME and Komers R: Renal haemodynamic changes in diabetes. In: Proceedings of the 15th International Diabetes Federation Congress, Kobe, Japan, p.26, 1994
11.Cao Z, Wookey PJ, Komers R, and Cooper ME: The renal amylin binding site in rat models of hypertension. In: Proceedings of the 31th Annual Scientific Meeting of The Australian and New Zealand Society of Nephrology; Canberra, Australia, 1995
12.Komers R and Cooper ME: The role of nitric oxide (NO) in renal sodium handling in experimental diabetes. Diabetologia 38 (Suppl 1): A265, 1995
13.Komers R, Pelikánová T, and Kazdová L: Effect of euglycaemic hyperinsulinemic clamp on renal function and NO2-/NO3- excretion in healthy subjects. In: Proceedings of the 1st International Congress of Clinical Physiology, Stockholm, 1995
14.Maly J, Komers R: Renal excretion of uric acid and metabolic control in patients with Type II diabetes. In: Proceedings of the European Diabetic Nephropathy Study Group, 9th meeting, Parma, Italy, p. 117, 1996
15.Komers R, Pelikanova T and Kazdova L: Effect of euglycaemic hyperinsulinemic clamp on renal function and NO2-/NO3- excretion in healthy subjects and Type 2 (non-insulin- dependent) diabetic patients. Diabetologia 39 (Suppl 1): PS 906, 1996
16.Komers R, Pelikánová T, and Kazdová L: Effect of hyperinsulinemia on renal excretory function and excretion of nitric oxide(NO)metabolites in healthy subjects Am J Hypertension 10 (Suppl 1): 180A, 1997
17.Komers R, Pelikánová T, and Kazdová L: Effect of hyperinsulinemia on renal excretory function and excretion of nitric oxide(NO)metabolites in healthy subjects and patients with NIDDM.In: Proceedings of the 5th International Symposium on Hypertension associated with Diabetes Mellitus, Sunshine Coast, Australia, 1997
18.Pelikanova T, Kazdova L, Komers R, Zak A: Die Stickoxymetabolite im Plasma und die insulininduzierte Oxydierbarkeit der Lipoproteine mit geringer Dichte (LDL) bei Kranken mit insulinunabhangigem Diabetes mellitus (NIDDM). Diabetes und Stoffwechsel 6, Suppl.3: 28, 1997. XIV. Internationales Donausymposium uber Diabetes mellitus, Prague, Czech Republic, 1997
19.Vrana A, Kazdova L, Divisova J, Chvojkova R, and Komers R: Metabolic effects of troglitazone in animal model of severe hypertriglyceridemia. In: Proceedings of "Enzymes, Receptors and Drugs in Obesity and Atherosclerosis" of the International Society for Enzymology, Toronto, Canada, p. 98, 1998
20.Komers R, Komersova K, Kazdova L, Pelikanova T: ACE inhibitor (ACEI) ramipril, but not angiotensin AT1 receptor blocker (AT1B) losartan, enhances L-arginine-induced renal vasodilation in humans. J Amer Soc Nephrol 9: A1732; 1998
21.Komers R, Oyama TT, Lindsley JN, Anderson S: Renal effects of systemic and local inhibition of neuronal NOS in experimental diabetes. In: Proceedings of the 12th Annual Group Meeting of the European Diabetic Nephropathy Study Group, Gdansk, Poland, p.24, 1999
22.Komers R, Oyama TT, Lindsley JN, Anderson S: Renal effects of local inhibition of neuronal NOS (NOS1) in control and diabetic rats. J Amer Soc Nephrol 10: A3469; 1999
23.Komers R, Lindsley JN, Oyama TT, Anderson S: Renal protein expression and effects of acute inhibition of cyclooxygenase-2 in diabetes mellitus. J Amer Soc Nephrol 11: 2000, 646A.
24.Al-Nimri MA, Komers R, Subramanya AR, Lindsley JN, Oyama TT, and Anderson. S: Nitric Oxide (NO) in Polycystic Kidney Disease (PKD). J Amer Soc Nephrol 11: 2000, 612A.
25.Komers R, Oyama TT, Lindsley JN, Ledbetter S, Anderson S: Effect of transforming growth factor-beta neutralizing antibody on progressive renal disease in the rat. J Amer Soc Nephrol 11: 2000, 623A.
26.Komers R, Reed JF, Lindsley JN, Oyama TT, Schutzer WE, Scott L. Mader SL, and Anderson S. Expression of caveolin-1 (CAV-1) in renal cortex of normal and diabetic rats. J Amer Soc Nephrol 12: 2001, A4392
27.Komers R, Tian W, Lindsley JN, Oyama TT, Cohen D, and Anderson S. Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes . J Amer Soc Nephrol 12: 2001, A2962
28.Komers R, Oyama TT, Lindsley JN, and Anderson S. Long-term inhibition of neuronal nitric oxide (NO) synthase (NOS1) postpones development of proteinuria in uninephrectomized diabetic rats. J Amer Soc Nephrol 12: 2001, A4391
- Komers R, Lisy O, Burnett JC Jr., Anderson S. Renal immunohistochemical expression of dendroaspis natriuretic peptide in normal and diabetic rats. J Amer Soc Nephrol 12: 2001, A2963
30.Komers R, Lindsley JN, Oyama TT, Anderson S.Functional expression of endothelial nitric oxide (NO) synthase (NOS3) in the diabetic kidney cortex. J Hypertension 20: 2002 (Suppl. 1), P 0785
31.Komers R, Lindsley JN, Oyama TT, Anderson S. Effects of Long-Term Cyclooxygenase-2 (COX-2) Inhibition on the Development of Nephropathy in Uninephrectomized Diabetic Rats. J Amer Soc Nephrol 13: 2002, A166
32.Komers R, Reed JF, Lindsley JN, Oyama TT, Mader SM, Anderson S. Functional Expression of Endothelial Nitric Oxide (NO) Synthase (eNOS, NOS3) and Caveolin-1 (CAV-1) in Diabetic Kidney Cortex. J Amer Soc Nephrol 13: 2002, A532
33.Jana Zdychova, Terezie Pelikanova, Ludmila Kazdova, and Radko Komers. Renal cortical expression of Akt kinase and PTEN in Zucker diabetic fatty rats. In: Proceedings of the 18th International Diabetes Federation Congress, Paris, France, August 2003.
- Komers R, Schutzer W, Reed J, Oyama TT, Anderson S. Effects of p38 MAPK inhibition on vascular reactivity in experimental diabetes. In: Proceedings of the 18th International Diabetes Federation Congress, Paris, France, August 2003.
35.Komers R, Lindsley JN, Oyama TT, Anderson S. p38 Mitogen-Activated Protein Kinase Expression and Activity in Diabetic Renal Cortex. Role of Metabolic Control", J Amer Soc Nephrol 2003, 14: PO302.
36.Komers R, Cahova M, Zdychova J, Lindsley JN, Anderson S. Expression of Cyclooxygenase (COX) Isoforms in Renal Cortex of Zucker Diabetic Fatty Rats (ZDF). J Amer Soc Nephrol 2003, 14: PO440
37.Radko Komers, Jessie L. Lindsley, Terry T. Oyama, Sharon Anderson. p38 Mitogen-Activated Protein Kinase (MAPK) Expression and Activity in Diabetic Renal Cortex. In: Proceedings of the 17th Annual Group Meeting of the European Diabetic Nephropathy Study Group, Bergamo, Italy, 2004.
38.Zdychova J, Kazdova L, Pelikanova T, Komers R. Renal activity and expression of Akt kinase in different models of diabetes. Diabetologia 2004, 47: Suppl.1, A395.
39.Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JL, Anderson S. Gender Hormones and the Progression of Experimental Polycystic Kidney Disease (PKD). J Amer Soc Nephrol 2004, 15: PO572
40.Komers R, Zdychova J, Lindsley JN, Anderson S. Renal Cortical Expression of Akt Kinase Is Increased in Zucker Diabetic Fatty Rats (ZDF) and Controls mTOR Phosphorylation. J Amer Soc Nephrol 2004, 15: PO890.
41.Horackova M, Schuck O, Charvat J, Komers R, Teplan V, Kvapil M: Effect of rofecoxib on parameters of renin-angiotensin-aldosterone system, glomerular filtration and proteinuria in elderly subjects with renal insufficiency. In: Proceedings of the XVII Danube Symposium in Nephrology, 2004.
42.Lecian D,Demova H, Zdychova J, Teplan V, Komers R. Effect of atorvastatin on albuminuria in nitric oxide-deficient model of hypertension. Nephrol Dial Transplant 2005, 20 (Suppl. 5), v34.
43.Komers R, Oyama TT, Lindsley JL, Anderson S. Effects of acute p38 MAP kinase inhibition on blood pressure and renal hemodynamics in normal and diabetic rats. J Amer Soc Nephrol 2005, 16: PO1443.
44.Zdychova J, Lindsley JN, Anderson S, Komers R. Renal Akt kinase signaling in Zucker diabetic fatty rats (ZDF). Proceedings. Cell Signaling World 2006. Signal transduction Pathways as Therapeutic Targets. Luxembourg, p. 253, 2006.